Transcript Metaplasis BioMedical Consulting

Zestagen S.A.
Services Summary
2015
Nassos Alevizopoulos, PhD, MBA
Managing Partner
[email protected]
1
v6/Q1 15
Q1/15 – all rights reserved
Meta-plasis (trans-formation) at a glance
 boutique biotech & pharma consulting

Support project mgmt. or investment decisions

Sector dedication
what we do
 Analyze, integrate & transform

Extreme focus on science (Medline, WIPO)

Commercial & financial info (databases)
how we do it
 Excellent value for money
2

Minuscule team (EU/US) with broad international network

Consultants with active executive roles

Direct access to specialized associated networks

We understand & get down into the project’s core science

Virtual operations (timesheet, availability)

Rapid turnaround
Q1/15 – all rights reserved
why us?
Key Metaplasis people
Nassos Alevizopoulos, PhD, MBA
CH
CH
Andrei Lyne, MBA
USA
• 20y of experience in
biopharmaceutical development
(large molecules, devices)
• 17y of experience in life
sciences (drug development,
small molecules, diagnostics)
• 12y with UBS Investment Bank
in London & New York, most
recently as Executive Director
• currently CEO of Zestagen SA
(preclinical cancer mAb; CH)
• currently CEO of APIM
Therapeutics AS (cancer
biotech, Norway)
• over 100 transactions across 25
countries for deals worth an
aggregate $8 billion;
• partner at Ventac Partners
• currently CFO at Synpromics
Ltd.
• oversaw an orphan drug
designation in pancreatic cancer
• COO/CEO positions in various
biopharma companies (US/GR)
• cofounded startup companies
• Business Planning & Analysis
with Novartis
• Brunner Prize for the best of
181 PhDs in Molecular Biology
(Lausanne Univ.); also MBA from
Lausanne
3
Kostas Alevizopoulos, PhD
• previously CEO/CSO/Head of
R&D in various biotech
companies (US/CH/GR)
• cofounded startup companies
• Ph.D. in Molecular Oncology
(Univ. of Lausanne)
• trained in European patent
law (Univ. of Strasbourg)
Q1/15 – all rights reserved
• Experience in biopharma, buyside and sell-side M&A, IPOs,
convertible bonds etc.
• BA from Oxford Univ. (Baker
Scholarship)
• MBA in finance from New York
Univ. (Directors Fellowship)
1. Metaplasis can assist academic institutions with tech transfer
 Technology appraisal

Scientific analysis

Intellectual Property / Freedom to Operate (FTO) analysis

SWOT analysis

Evaluation of partnering potential

Tech valuation

Tech agreement drafting (Sponsored Research, CRADA)

Collaboration with Univ. Tech Transfer Office (TTO)
TTO
TTO
academic
discovery
4
Spinoff
formation
Commercializable?
Q1/15 – all rights reserved
Seed $
angels
1. Metaplasis can assist academic institutions with tech transfer (cont’ed)
 Case study 1: NewCo formation around cutting-edge cancer IP

Unique mAb against cancer

IP licensed from a European Institution to NewCo

Seed investor found
 Case study 2: a Scandinavian University
 Position novel anti-cancer therapeutics
 Case study 3: mandate from a group of Canadian investors (on going)
 Scout for promising tech in N. America for NewCo formation
 Case study 4: technology appraisal for a Chinese biopharma company
 Report & annexes delivered in 10 business days
5
Q1/15 – all rights reserved
2. Metaplasis can assist with preclinical drug development effort
 Drawing from hands-on experience (running our own companies) we can
assist with:

Preclinical development plan generation

Outsourcing decisions (chose relevant Contract-Research Organizations)

Scientific & regulatory preparation for Guidance Regulator meetings (Scientific
Advice, Protocol Assistance, IND/IMPD)
 Case studies
 Assist a clinical CRO to attract an assignment by a vaccine developer
for preclinical regulatory assistance
6
Q1/15 – all rights reserved
2. Metaplasis can assist with preclinical drug development effort (cont’ed)

Sample Preclinical
Development Plan
7
Q1/15 – all rights reserved

Time

Actions

Cost

Incumbent

Single Page format
3. Metaplasis can assist with investment decisions

c1: rNPV
Product/company
valuations

risk-adjusted
NPV


comparables

EV/EBITDA
Case study 1:
Estimate value of a
Scandinavian
biotech company
c2: EV/EBITDA
with rNPV

Case study 2
EV/EBITDA analysis
of a Greek
healthcare takeover
target
8
Q1/15 – all rights reserved
4. Metaplasis can assist with business development of market-ready products

Strategy development for market-ready (i.e. approved) products entering new
geographic markets
9

Identification of potential partners (licensors, buyers/sellers)

Development of client company materials (non-conf & conf)

Deal Structures & Value Sharing (e.g. up-fronts vs. delayed payments)

Network in Balkans, MENA, CIS, some EU countries, some States

pharmaceuticals, medical devices, neutraceuticals, herbals
Q1/15 – all rights reserved
4. Metaplasis can assist with business development of market-ready products (c’ed)
Case: ranking candidate Greek distributors for an Asian company
10
Q1/15 – all rights reserved
Summary of Metaplasis Services
1. Technology appraisals (academic institutions, biotech, investors…)
2. Assistance with preclinical drug development (biotech)
3. Assistance with investment decisions (biotech, investors)
4. Business development (market-ready products for pharma, devices etc.)
11
Q1/15 – all rights reserved
Zestagen S.A.
Thank You
Nassos Alevizopoulos, PhD, MBA
Managing Partner
[email protected]
12
Q1/15 – all rights reserved